Medizinische Universität Graz - Research portal
Selected Publication:
SHR Neuro Cancer Cardio Lipid Metab Microb
Loper, K; Sugrue, MW; Raval, JS; Schwartz, JY; Land, K; Koh, M; Mengling, T; Greinix, H; Halter, JP; Celluzzi, CM; Chaudhri, M.
Adverse event reporting for cellular therapy products: Current status and future directions.
Transfusion. 2020; 60(12):2815-2827
Doi: 10.1111/trf.16062
Web of Science
PubMed
FullText
FullText_MUG
- Co-authors Med Uni Graz
- Greinix Hildegard
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- Adverse event (AE) and adverse reaction (AR) reporting are key components of patient safety and surveillance systems. Review and analysis of this data yields opportunities for process improvement, product information and interventions, and can lead to improved patient outcomes and donor safety overall. AE and AR reporting for cellular therapy products is fragmented and not well characterized in a central reference. This review article, authored by experts from various organizations, serves to summarize the current state of reporting and offers opportunities for streamlining and coordination, as well as key reference for professionals in this field. © 2020 AABB.